Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sangamo Therapeutics, Inc. SGMO -- Ignore unavailable to you. Want to Upgrade?

To: Pseudo Biologist who wrote (35)	2/14/2001 7:22:11 AM
From: nigel bates	Read Replies (1) \| Respond to of 368

Feb. 14 /PRNewswire/ -- Gendaq Ltd announced today the publication of two research papers describing major improvements to zinc finger engineering technology enhancing the ability to exclusively target and regulate the expression of any given gene. The papers, entitled ``Improved Binding Specificity from Polyzinc Finger Peptides by Using Strings of Two-Finger Units'' and ``Design of Polyzinc Finger Peptides with Structured Linkers'', appear back-to-back in this week's issue of the Proceedings of the National Academy of Sciences of the USA. The research provides new methods of constructing improved zinc finger protein multimers, which are capable of binding unique DNA sequences present in genomic DNA with high specificity. Gendaq uses these proteins to make Z-Switches(TM) to regulate target genes for applications in functional genomics and therapy. The zinc finger engineering work was undertaken in collaboration with the Medical Research Council's Laboratory of Molecular Biology in Cambridge. Authors of the papers are Dr. Michael Moore and Dr. Yen Choo, both of Gendaq, and Sir Aaron Klug of the Medical Research Council, who is a Founding Scientist of Gendaq. Speaking in London at the conference ``Innovations in Drug Target Validation'', Dr. Choo described how Gendaq uses such proteins to elucidate gene function and to validate potential drug targets in the pharmaceutical sector. ``Our multi-finger proteins improve on those created by conventional technology in that they have exceptionally high specificity. We have used our zinc finger engineering approach to knock out a number of pharmaceutically important gene targets and can do so in a high-throughput fashion,'' commented Dr. Choo. Gendaq Ltd is a privately held biotechnology company that specializes in gene regulation. The Company's technology enables the up- and down-regulation of any gene in any eukaryotic cell and can be applied in areas as diverse as human therapeutics, gene therapy, agricultural biotechnology, disease diagnosis and functional genomics...